Neogenomics (NEO) executive compensation, 2026 proxy

Tony Zook, Director and Chief Executive Officer, was paid $9.1M in 2025. The CEO-to-median-employee pay ratio was 93:1, on median employee pay of $101,144.

Filed
April 6, 2026
Annual meeting
May 21, 2026
Pay year
2025
Named executives
7
CEO total pay
$9.1M2025
CEO to median employee
93:1median $101,144
CEO pay in equity
88%$8M in awards
Prior say-on-pay support
82%of votes cast
CEO Target Bonus %
100%Equal to base pay
Say-on-Pay Support
81.77%Prior year support
CEO Stock Awards
$3,999,997Grant date fair value

How Zook was paid

$9.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary7%Stock awards44%Option awards44%Non-equity incentive6%All other compensation0%

Named executive officers

ExecutiveTotal
Tony ZookDirector and Chief Executive Officer$9,127,092
Christopher SmithFormer Director and Former Chief Executive Officer$4,045,937
Jeffrey ShermanChief Financial Officer$4,681,428
Warren StoneChief Commercial Officer$5,068,830
Alicia OlivoExecutive Vice President, General Counsel and Business Development$3,049,999
Gary PassmanChief Culture Officer$2,443,195
Melody HarrisFormer Chief Operations Officer and Former President, Oncology Data Solutions$3,692,445

What changed and why

  • $9.1MTony Zook received $9,127,092 in total compensation for 2025 following his appointment as Chief Executive Officer.
  • Premium-priced stock options were introduced for executive grants in 2025 to increase pay-for-performance alignment.
  • 81.77%Say-on-pay received 81.77% support at the previous annual meeting of stockholders.
  • 60%The company engaged with stockholders representing over 60% of outstanding shares during outreach periods in 2025.
  • Targeted retention actions were implemented for specific executive leaders based on stockholder feedback.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.